NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS NASDAQ) stock market data APIs
$34.6036
-1.66(-4.8%)
as of February 6, 2026
Try our APIs with
free plan!
NewAmsterdam Pharma Company N.V. Ordinary Shares Financial Data Overview
Price chart is built with
Anychart
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Prev. Close
34.6036
Open
32.9414
High
35.074
Low
32.2935
52 wk Range
14.06-42
Market Cap
3 635 M
Shares Outstanding
113 M
Revenue
35 243 K
EPS
-0.61
Beta
0.069
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with NewAmsterdam Pharma Company N.V. Ordinary Shares (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get NewAmsterdam Pharma Company N.V. Ordinary Shares data using free add-ons & libraries
Get NewAmsterdam Pharma Company N.V. Ordinary Shares Fundamental Data
NewAmsterdam Pharma Company N.V. Ordinary Shares Fundamental data includes:
- Net Revenue: 35 243 K
- EBITDA: -202 720 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get NewAmsterdam Pharma Company N.V. Ordinary Shares Earnings data
$
19.99
/mo.
What’s included:
- Latest Release: 2025-11-05
- EPS/Forecast: -0.4033
Get NewAmsterdam Pharma Company N.V. Ordinary Shares End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
NewAmsterdam Pharma Company N.V. Ordinary Shares News
New
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAARDEN, The Netherlands and MIAMI, Feb. 06, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceut...
NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit
NewAmsterdam Pharma N.V. NAARDEN, The Netherlands and MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage...
Assessing NewAmsterdam Pharma (NAMS) Valuation After Recent Share Price Volatility
NewAmsterdam Pharma (NAMS) is back on investors’ radar after recent trading left the stock at $31.86, with mixed short term returns and a much stronger 1 year and 3 year track record. See our lates...
Atherosclerotic Cardiovascular Disease Market to Register Incremental Growth at a CAGR of 4.9% During the Forecast Period (2025–2034) | DelveInsight
DelveInsight Business Research LLP The atherosclerotic cardiovascular disease market in the 7MM is expected to show positive growth during the forecast period (2025–2034), mainly attributed to the ...
Get NewAmsterdam Pharma Company N.V. Ordinary Shares fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
